Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-AL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Meng, Yuan, Deng, Biping, Rong, Luan, Li, Chuo, Song, Weiliang, Ling, Zhuojun, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Xiong, Xiujuan, Chen, Xiaoli, Pan, Jing
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8279746/
https://ncbi.nlm.nih.gov/pubmed/34277400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.640166
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados